MedTrace Logo

Medication, Weight Gain and GI Hormones

NCT00384332 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-07-31

Study results available
· View outcomes & findings →

Summary

This is an 8 week study that compares two medications. One medication is olanzapine (5-20 mg daily) whereas the other medication is an orally disintegrating medication. Both medications are used to treat depressed bipolar patients. The main focus of this study is the comparison of these two medications on gastro-intestinal hormones and weight gain.

Conditions

Interventions

DRUG

orally-disintegrating olanzapine

5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.

DRUG

regular olanzapine

5-20 mg. olanzapine daily for approximately 8 weeks.

Sponsors & Collaborators

Principal Investigators

  • Richard C. Shelton, M.D. · Vanderbilt University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00384332 on ClinicalTrials.gov